Triplet Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Triplet researched RNA-based gene-silencing treatments for repeat-expansion disorders, including Huntington’s disease.
02 / Triplet Therapeutics FAILURE REASONS
Failure reasons
Its co-founder linked the wind-down to discouraging trial results from other companies pursuing related treatments. Those results, together with weaker biotech financing, made further fundraising difficult. This is not evidence that Triplet’s own human trial failed.
03 / EVENT HISTORY
Events in the structured record
- Staff reduction and wind-down
October reports described successive reductions from about 55 employees to a small leadership group tasked with preserving research data and an ongoing natural-history study.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Related companies reported disappointing trial results
- 02
Confidence and financing for further development weakened
- 03
Workforce was reduced in stages
- 04
Operations wound down while research data was preserved